JiangXi Tianxin Pharmaceutical Co Ltd
SSE:603235
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (35.8), the stock would be worth ¥2.71 (90% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 341.7 | ¥25.8 |
0%
|
| 3-Year Average | 35.8 | ¥2.71 |
-90%
|
| 5-Year Average | 40.7 | ¥3.07 |
-88%
|
| Industry Average | 37.1 | ¥2.8 |
-89%
|
| Country Average | 26.4 | ¥1.99 |
-92%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
J
|
JiangXi Tianxin Pharmaceutical Co Ltd
SSE:603235
|
11.3B CNY | 341.7 | 18.3 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
285.6B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | -38 725.3 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
100.2B ZAR | 15.5 | 10.4 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
67.9B USD | -88 198.6 | 38 368.9 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
59.7B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
38.4B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
31.4B EUR | 69.7 | 173.5 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
35.5B USD | 45.4 | -3 256.9 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
29.7B ZAR | 4.9 | 6.9 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 13.7 |
| Median | 26.4 |
| 70th Percentile | 52.8 |
| Max | 2 279 450.9 |
Other Multiples
JiangXi Tianxin Pharmaceutical Co Ltd
Glance View
Perched in the vibrant province of Jiangxi, China, JiangXi Tianxin Pharmaceutical Co., Ltd. has carved a niche for itself as a formidable player in the pharmaceutical industry. Established with a clear vision to fuse traditional Chinese medicine with state-of-the-art technological advancements, the company specializes in the development and production of high-quality pharmaceutical products. JiangXi Tianxin's journey is a testament to its commitment to providing effective health solutions, emphasizing the importance of research and development to foster innovation within its product lines. The company operates with a holistic perspective, aiming to address various health concerns by integrating traditional wisdom with modern pharmaceutical practices. At the heart of its operations, JiangXi Tianxin's business model thrives on a diversified product portfolio, which spans active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. This strategic diversification allows the company to mitigate risks associated with market fluctuations while tapping into multiple revenue streams. By focusing on the production of APIs, JiangXi Tianxin ensures a robust supply chain necessary for developing essential medicines. Furthermore, its ability to manufacture a broad spectrum of products facilitates profitability through an economy of scale, allowing the company to maintain competitive pricing. By aligning its operational strategies with market demand and regulatory standards, JiangXi Tianxin not only sustains its growth but also fortifies its standing as a trusted pharmaceutical entity in both domestic and international markets.